Influence of statin treatment in a cohort of patients admitted for COVID-19
© 2021 Elsevier España, S.L.U. All rights reserved..
Aims and objectives: Statins have been proposed as potentially useful agents for modulating the host response in COVID-19. However, solid evidence-based recommendations are still lacking. Our aim was to study the association between statin use and clinical outcomes in a large cohort of hospitalized patients with SARS-CoV-2 infection, as well as the specific consequences of chronic treatment withdrawal during hospital admission.
Material and methods: Retrospective observational study including 2191 hospitalized patients with confirmed SARS-CoV-2 infection.
Results: Mean age was 68.0±17.8 years and 597 (27.3%) patients died during follow-up. A total of 827 patients (37.7% of the whole sample), received chronic treatment with statins. Even though they underwent more frequent admissions in critical care units, chronic treatment with statins was not independently associated with all-cause mortality [HR 0.95 (0.72-1.25)]. During the whole hospital admission, 371 patients (16.9%) received at least one dose of statin. Although these patients had a significantly worse clinical profile, both treatment with statins during admission [HR 1.03 (0.78-1.35)] and withdrawal of chronic statin treatment [HR 1.01 (0.78-1.30)] showed a neutral effect in mortality. However, patients treated with statins presented more frequently hepatic cytolysis, rhabdomyolysis and thrombotic/hemorrhagic events.
Conclusions: In this large cohort of hospitalized COVID-19 patients, statins were not independently associated with all-cause mortality during follow-up. Clinically relevant statin-associated adverse effects should be carefully monitored during hospital admission.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:158 |
|---|---|
| Enthalten in: |
Medicina clinica (English ed.) - 158(2022), 12 vom: 24. Juni, Seite 586-595 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rey, Juan R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse effects |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.medcle.2022.05.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34215561X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34215561X | ||
| 003 | DE-627 | ||
| 005 | 20231226013438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medcle.2022.05.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1140.xml |
| 035 | |a (DE-627)NLM34215561X | ||
| 035 | |a (NLM)35693916 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rey, Juan R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Influence of statin treatment in a cohort of patients admitted for COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Aims and objectives: Statins have been proposed as potentially useful agents for modulating the host response in COVID-19. However, solid evidence-based recommendations are still lacking. Our aim was to study the association between statin use and clinical outcomes in a large cohort of hospitalized patients with SARS-CoV-2 infection, as well as the specific consequences of chronic treatment withdrawal during hospital admission | ||
| 520 | |a Material and methods: Retrospective observational study including 2191 hospitalized patients with confirmed SARS-CoV-2 infection | ||
| 520 | |a Results: Mean age was 68.0±17.8 years and 597 (27.3%) patients died during follow-up. A total of 827 patients (37.7% of the whole sample), received chronic treatment with statins. Even though they underwent more frequent admissions in critical care units, chronic treatment with statins was not independently associated with all-cause mortality [HR 0.95 (0.72-1.25)]. During the whole hospital admission, 371 patients (16.9%) received at least one dose of statin. Although these patients had a significantly worse clinical profile, both treatment with statins during admission [HR 1.03 (0.78-1.35)] and withdrawal of chronic statin treatment [HR 1.01 (0.78-1.30)] showed a neutral effect in mortality. However, patients treated with statins presented more frequently hepatic cytolysis, rhabdomyolysis and thrombotic/hemorrhagic events | ||
| 520 | |a Conclusions: In this large cohort of hospitalized COVID-19 patients, statins were not independently associated with all-cause mortality during follow-up. Clinically relevant statin-associated adverse effects should be carefully monitored during hospital admission | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adverse effects | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Morbidity | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Statins | |
| 650 | 4 | |a Treatment with drawal | |
| 700 | 1 | |a Merino Llorens, José Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Iniesta Manjavacas, Ángel Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Rosillo Rodríguez, Sandra Ofelia |e verfasserin |4 aut | |
| 700 | 1 | |a Castrejón-Castrejón, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Arbas-Redondo, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Poveda-Pinedo, Isabel Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Tebar-Márquez, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Severo-Sánchez, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Rivero-Santana, Borja |e verfasserin |4 aut | |
| 700 | 1 | |a Juárez-Olmos, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Cossiani, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Buño-Soto, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Valle, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Herrero-Ambrosio, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a López-de-Sá, Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a Caro-Codón, Juan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina clinica (English ed.) |d 2015 |g 158(2022), 12 vom: 24. Juni, Seite 586-595 |w (DE-627)NLM308740777 |x 2387-0206 |7 nnns |
| 773 | 1 | 8 | |g volume:158 |g year:2022 |g number:12 |g day:24 |g month:06 |g pages:586-595 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medcle.2022.05.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 158 |j 2022 |e 12 |b 24 |c 06 |h 586-595 | ||